aXichem: Progressing Nicely in the Nutraceuticals Segment - Redeye

Redeye endorses aXichem signing a business collaboration agreement with GCV Life to commercialize aXivite in the fast-growing Indian market and we are also encouraged to learn that the company has seen an increased interest for the product in both Europe and the US during the beginning of 2022. Consequently, we see excellent growth prospects for aXivite going forward and continue to argue that aXichem has a very exciting year ahead.

Länk till analysen i sin helhet: https://www.redeye.se/research/832595/axichem-progressing-nicely-in-the-nutraceuticals-segment?utm_source=finwire&utm_medium=RSS